Dr. Gaillard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
201 North Broadway Street
Viragh BLDG 10th FL
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012
- Johns Hopkins UniversityResidency, Internal Medicine, 2006 - 2009
- Duke University School of MedicineClass of 2006
Certifications & Licensure
- MD State Medical License 2009 - 2026
- PA State Medical License 2020 - 2022
- NC State Medical License 2012 - 2017
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer Start of enrollment: 2013 Feb 01
- Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA Start of enrollment: 2014 Sep 01
- A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Start of enrollment: 2016 Jun 01
Publications & Presentations
PubMed
- Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication.Jayaprakash Mandal, Tiffany Nicole Jones, Juliane Marie Liberto, Stephanie Gaillard, Tian-Li Wang
Cancer Research. 2024-11-15 - Association of glutaminase expression with immune-suppressive tumor microenvironment, clinicopathologic features, and clinical outcomes in endometrial cancer.Shiho Asaka, Neha Verma, Ting-Tai Yen, Jessica L Hicks, Hiro Nonogaki
International Journal of Gynecological Cancer. 2024-11-04 - 2 citationsPembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series.Shannon M Glynn, Stephanie Gaillard, Rebecca L Stone, Amanda N Fader, Anna L Beavis
Gynecologic Oncology Reports. 2024-06-01
Journal Articles
- T Cell-Inflamed Phenotype and Increased Foxp3 Expression in Infiltrating T-cells of Mismatch-Repair Deficient Endometrial CancersStephanie Gaillard, MD, Nature
Press Mentions
- Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
- Johns Hopkins Medicine Researchers Awarded Nearly $8 Million from Break Through Cancer FoundationApril 26th, 2022
- 2019 Gynecologic Cancer Survivorship Conference: Thriving Through Education and ConnectionSeptember 5th, 2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: